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The prognostic value of the carcinoembryonic antigen cell adhesion molecule 1 (CEACAM1) in melanoma was
demonstrated more than a decade ago as superior to Breslow score. We have previously shown that intercellular
homophilic CEACAM1 interactions protect melanoma cells from lymphocyte-mediated elimination. Here, we study the
direct effectsofCEACAM1onmelanomacell biology. Byemploying tissuemicroarraysand low-passageprimary cultures
of metastatic melanoma, we show that CEACAM1 expression gradually increases from nevi to metastatic specimens,
with a strongdominanceof theCEACAM1-Long tail splice variant.Using experimental systemsofCEACAM1knockdown
and overexpression of selective variants or truncation mutants, we prove that only the full-length long tail variant
enhancesmelanoma cell proliferation in vitro and in vivo. This effect is not reversed with a CEACAM1-blocking antibody,
suggesting that it is not mediated by intercellular homophilic interactions. Downstream, CEACAM1-Long increases the
expression of Sox-2, whichwe show to be responsible for the CEACAM1-mediated enhanced proliferation. Furthermore,
analysis of the CEACAM1 promoter reveals two single-nucleotide polymorphisms (SNPs) that significantly enhance
the promoter's activity compared with the consensus nucleotides. Importantly, case-control genetic SNP analysis of
134 patients with melanoma and matched healthy donors show that patients with melanoma do not exhibit the
Hardy-Weinberg balance and that homozygous SNP genotype enhances the hazard ratio to develop melanoma by
35%. These observations shed newmechanistic light on the role of CEACAM1 in melanoma, forming the basis for
development of novel therapeutic and diagnostic technologies.
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Melanoma accounts for nearly 4% of all skin cancers, and it causes 75% of
skin cancer–related deaths worldwide. Estimates for 2013 are that 76,690
invasive melanomas will be diagnosed in the United States and that
melanoma could claim 9480 lives. Melanoma is the fifth most common
cancer in men and seventh in women in the United States [1]. Disease
progression and development of metastasis require stepwise acquisition of
aggressive characteristics [2], including resistance to the immune system
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last years, the US Food and Drug Administration approved the anti-
Cytotoxic T-Lymphocyte Antigen 4 monoclonal antibody (mAb)
(ipilimumab), the selective BRAFV600E inhibitors vemurafenib and
dabrafenib, as well as the mitogen-activated protein kinase kinase
enzymes (MEK) inhibitor trametinib for the indication of metastatic
melanoma. Although these drugs show proven benefit in overall survival
[4–6], the treatment for melanoma is still far from being satisfactory.
Carcinoembryonic antigen cell adhesion molecule 1 (CEACAM1) is a
transmembrane glycoprotein that belongs to the carcinoembryonic
antigen family, which encompasses several forms of proteins with different
biochemical properties, all encoded on chromosome 19 [7]. CEACAM1 is
composed of sequentially ordered extracellular immunoglobulin-like
domain(s), a single-pass transmembrane domain, and a cytoplasmic tail.
Different transcriptional splice variants give rise to several isoforms, which
differ in the number of Ig-like domains at the extracellularN terminus, the
length of the cytoplasmic tail, and the presence of Alu repeats. The most
common and sequenced variants are short and long forms of CEACAM1-
3 and CEACAM1-4. A long form contains immunodominant tyrosine-
based inhibitory motif (ITIM), and a short form is devoid of ITIM [7].
CEACAM1 interacts homophilically with CEACAM1 and hetero-
philically with CEACAM5, but not with other CEACAM proteins [8].
CEACAM1 is expressed on a variety of cells, e.g., some epithelial cells,
melanoma, and activated lymphocytes [7].
Many different functions have been attributed to the CEACAM1
protein, including antiproliferative properties in carcinomas of the
colon and prostate and central involvement of CEACAM1 in
angiogenesis and insulin clearance as well as in immune-modulation
{reviewed in [7,9]}. T cell inhibition through engagement of
CEACAM1 has been demonstrated by direct T cell receptor cross-
linking [10] and through binding of Neisseria opacity-associated
proteins [11]. Inhibition is mediated through the recruitment of
SHP-1 phosphatase to the cytosolic ITIM sequences [7]. We have
previously shown that CEACAM1 homophilic interactions inhibit NK
cell–mediated killing independently of major histocompatibility
complex class I recognition [12–14]. We have further demonstrated
that CEACAM1 inhibits cytotoxicity and interferon gamma (IFNγ)
release of tumor-infiltrating lymphocytes [15].Moreover, we found that
an IFNγ-driven up-regulation of CEACAM1 on melanoma cells
surviving tumor-infiltrating lymphocyte–mediated attack renders them
evenmore resistant [16]. Following these findings, we developed a novel
approach for melanoma immunotherapy, which is based on functional
blocking of CEACAM1 with a specific mAb [17].
Thies et al. demonstrated that the presence of CEACAM1 on
primary cutaneous melanoma lesions strongly predicted the develop-
ment of metastatic disease [18]. This was in line with our findings that
CEACAM1 protects melanoma cells and inhibits both activated NK
cells [13] and activated T cells [15,16,19], emphasizing the potential
role played by CEACAM1 in the pathogenesis of metastatic melanoma
and justifying the development of a therapeutic approach that targets
the function of CEACAM1 [17]. Nevertheless, the direct effect of
CEACAM1 on the biology of melanoma cells, regardless of the
immune-protective effect, has never been tested. This is particularly
interesting in light of the following two points: 1) CEACAM1
expression predicts metastatic spread in melanoma xenograft models in
immunodeficient mice [20]; and 2) CEACAM1 suppresses cell
proliferation in othermalignancies, such as colon [21] and prostate [22].
Here, we show that CEACAM1 is gradually upregulated during
melanoma development and progression. It facilitates the proliferationof melanoma cells in a Sox-2–dependent manner. Two single-
nucleotide polymorphisms (SNPs) found in the promoter region
enhance its activity, and homozygosity increases the risk of developing
melanoma by 35%. These observations highlight the direct pivotal role
of CEACAM1 in melanoma.
Methods
Cells and Antibodies
We used melanoma American Type Culture Collection (ATCC)
(Manassas, VA, USA) cell lines A375, G361, WM 115, SK MEL 5, SK
MEL 28, MeWo, WM 266-4, National Institutes of Health (NIH)
(Bethesda, MD, USA) cell lines 526mel and 624mel, as well as 40
primary cultures of metastatic melanoma [16,17]. All melanoma cells
were grown in RPMImedium supplemented with 10% FBS, 100 μg/ml
Pen/Strep, 2 mM L-Glutamine, 25 mM Hepes, and 1 mM sodium
pyruvate (Biological Industries, Beit Ha-Emek, Israel) and incubated in
37°C, 5% CO2 condition.
The antibodies used in this work are described in Table W1.
Flow Cytometry
MRG1, a homemade specific to CEACAM1 monoclonal mouse
antibody [23], was used to determine surface CEACAM1 expression.
A population of 100,000 cells was incubated with 0.1 μg of antibody
diluted in FACS buffer [phosphate-buffered saline (PBS), 0.02%
sodium azide, and 0.5% BSA] for 30 minutes on ice. After
incubation, cells were centrifuged 400g at 4°C for 5 minutes, and
supernatant was removed. Cells were then incubated on ice with
Fluorescein isothiocyanate (FITC)-conjugated secondary antibody
for 30 minutes, washed with FACS buffer, and analyzed with
FACSCalibur instrument (BD bioscience, San Jose, CA, USA) and
FlowJo software (Tree Star Inc, Ashland, OR, USA).
Cell Cycle
A population of 106 cells was pelleted, washed twice with PBS, and
fixated with 70% ethanol overnight. Following fixation, cells were
permeabilized with 0.05% Triton X (Sigma-Aldrich, Rehovot, Israel)
and stained with 1 μg/ml propidium iodine (Sigma). The analysis was
performed using a FACSCalibur instrument (BD Biosciences) and
FlowJo software (Tree Star Inc).
Western Blot Analysis
A population of 5 × 106 cells was washed with PBS and lysed in
radio immunoprecipitation assay buffer (RIPA) lysis buffer (Sigma)
supplemented with protease inhibitor cocktail (Roche, Basel,
Switzerland) on ice for 20 minutes. Insoluble material was removed
by centrifugation at 14,000 rpm for 10 minutes at 4°C. Protein
concentration was measured using Pierce BCA protein kit (Thermo
Scientific, Waltham, MA, USA). Proteins were separated by 10% to
12% sodium dodecyl sulfate–polyacrylamide gel electrophoresis,
transferred onto nitrocellulose membranes (Bio-Rad Laboratories,
Hercules, CA, USA), and incubated with specific antibodies. The
antigen-antibody complexes were visualized by standard
enhanced chemiluminescence reaction (Biological Industries, Beit
Ha-Emek, Israel).
Knockdown of CEACAM1
Generation of stable CEACAM1-silenced 526mel cells was
performed using commercially available target sequences cloned in
the MISSION short hairpin RNA system (lentiviral plasmids pLKO.1-
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sequence was used as negative control.
Generation of transient CEACAM1-silenced melanoma cells was
performed using commercially available Dharmacon siGENOME
Human SMARTpool (Thermo Scientific) small interference RNA
(siRNA) system. Cells were grown until 75% of the surface of the plate
and transfected for 24 hours with either experiment CEACAM1-specific
siRNA (10 nM) or nontargeting scramble siRNA as a negative control (10
nM) using jetPRIME reagent (Polyplus-transfection SA, Strasbourg,
France) according to the manufacturer's instructions. After 24 hours,
transfection mixtures were replaced with regular medium, and cells were
maintained in normal culture condition before the experiments.
Generation of Constructs
The expression system used in this work was pQCXIP/puro. All
fragments were subcloned into NotI/EcoRI sites. The various primers
that were designed for cloning are provided in Table W2. To create the
fusion proteins such as extracellular portion of CEACAM1 fused to
glycosyl phosphoinositol (GPI) anchor (EC-GPI) and CEACAM1
transmembrane domain with long tail portions fused upstream to green
fluorescent protein (GFP), preceded by the leader peptide of
CEACAM1 (GFP-CT-L), the polymerase chain reaction (PCR)–
driven overlap extension approach was used [23].
Generation of Viral Particles and Cell Transduction
Lentiviral or retroviral particles were produced by transient liposome-
mediated cotransfection (TurboFect; Thermo Scientific) of 293 T cells
with lentiviral or retroviral packaging plasmids and the vector
containing the experimental construct. Culture medium was replaced
6 hours after transfection with fresh complete Dulbecco's modified
Eagle's medium and incubated for an additional 42 hours. The
medium containing viral particles was collected and filtered through a
0.45-μm filter. Previously seeded cells were infected two consecutive
days (twice total) by the filtered virus-containingmediumwith 1 μg/ml
polybrene. Virus-containing medium was replaced after 6 hours with
fresh medium. Forty-eight hours after the second infection, selection
antibiotic [puromycin (1 μg/ml)] was added into the culture medium.
Knockdown of Sox-2
siRNA-mediated gene knockdown Trilencer-27 siRNA kit
(OriGene Technologies Inc, Rockville, MD) was used to downregulate
SOX2 expression in 003mel/CCM1-L (CEACAM1-Long) cells. Cells
were grown until 75% of the surface of the plate and transfected for
24 hours with either experiment SOX2-specific siRNA (10 nM) or
nontargeting scramble siRNA as a negative control (10 nM) using
jetPRIME reagent (Polyplus-transfection SA) according to the
manufacturer's instructions. After 24 hours, transfection mixtures
were replaced with regular medium, and cells were maintained in
normal culture condition before the experiments.
RNA Isolation and Reverse Transcription
Total RNA was isolated using TRI Reagent (Sigma-Aldrich,
Rehovot, Israel), according to the manufacturer's instructions. cDNA
was generated by high-capacity reverse transcriptase kit (Applied
Biosystems, Foster City, CA, USA) using random hexamer primers
according to the manufacturer's instructions.
Quantitative Real-Time Reverse Transcription–PCR
Expression levels of different genes were determined by quantita-
tive real-time reverse transcription–PCR (qRT-PCR). Primers(Sigma-Aldrich) were designed according to Primer Express software
guidelines (Applied Biosystems). The qRT-PCR reactions were run in
triplicate on LightCycler 480 system (Roche). Gene transcripts were
detected using LightCycler 480 SYBR Green I Master (Roche).
Reactions were normalized to Glyceraldehyde 3-phosphate dehydro-
genase (GAPDH) endogenous control. The detailed list of primers
used for qRT-PCR appears in Table W2.
Net Proliferation Assay
Melanoma cells (5 × 103) were seeded in triplicate wells in 96 F-well
microplates. Net proliferation was determined by standardized
(2,3-Bis-(2-Methoxy-4-Nitro-5-Sulfophenyl)-2H-Tetrazolium-5-
Carboxanilide) (XTT) colorimetric assay, according the manufac-
turer's instructions (Biological Industries).
Progression Tissue Microarray and Immunohistochemistry
Tissue Micro-Array (TMA) slides were provided by the National
Cancer Institute (NCI) (Bethesda, MD, USA) Cancer Diagnosis
Program and included 66 benign nevi, 90 primary tumors, and 74
metastases. Other investigators may have received slides from these
same array blocks. This study was approved by the Institutional
Review Board. TMAs were stained with standard protocols with mAb
MRG1 as described [17] and analyzed by an expert pathologist.
Intensity of CEACAM1 expression was scored from 0 (negative) to 3,
and percentages of expression were defined as 0 to 3 for 0% to 5%,
6% to 25%, 26% to 75%, and 76% to 100%, respectively. The
entire tissue cylinder from each case was evaluated.
Melanoma Xenograft Model
Melanoma cells (2 × 106) were injected subcutaneously to the thigh
of 7- to 8-week-old Severe Combined Immunodeficiency/Nonobese
Diabetic (SCID-NOD) mice to create human melanoma xenografts.
Mice were monitored three times per week for tumor volume by caliper
measurement. Tumor volume was calculated as: (small diameter)2 ×
(large diameter)/2. Each group included 8 to 10 mice. At the end of the
experiment, the tumors were extracted and homogenized for further
tests. All animal work was performed following approval of Sheba
Medical Center Internal Regulatory Board (IRB) (434/2010).
Microarray Expression Analysis
Total RNA was extracted and used as template to generate cDNA
and subsequent biotinylated target cRNA that was processed by an
Affymetrix GeneChip Instrument System (Affymetrix, Santa Clara,
CA, USA) according to the manufacturer's recommendations. The
complete description of this procedure is available at: http://
Affymetrix.com/support/technical/manual.affx. The Database of
Essential Genes (DEGs) were analyzed by Ingenuity Pathway
Analysis (Redwood City, CA, USA) (http://www.ingenuity.com).
Patients and Healthy Individuals
One hundred thirty-four patients with histopathologically confirmed
melanoma, who attended the Dermatological Clinic at Sheba Medical
Center from 2001 to 2008, were recruited. One hundred thirty-three
ethnically matched normal individuals, who came to the same medical
center during the same period for noncancer-related diseases, were
recruited as control group (IRB Approval No. 4183/2006). All
participants signed a written informed consent. DNA was extracted
from venous blood leukocytes from all patients with melanoma and
healthy individuals.
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SNPs within the CEACAM1 gene were selected from National
Center for Biotechnology Information (NCBI), www.ncbi.nlm.nih.
gov (Bethesda, Maryland) SNP database (http://www.ncbi.nlm.nih.
gov/snp). Only SNPs in exons were evaluated. SNPs within the
coding region that cause a synonymous change were excluded.
Validation status and rate of polymorphisms in the tested population
were taken into account. Genotyping was performed in 384-well
microplates and determined by Matrix Assisted Laser Desorption
Ionization Time-of-Flight (MALDI-TOF) Sequenom (Sequenom,
San Diego, CA) platform as described previously [24]. Genotyping
assays were designed as iPLEX reactions using SpectroDESIGNER
software version 3.1 (Sequenom). The list of amplification and
extension primers is provided in Table W3.
CEACAM1 Promoter Functional Tests
A DNA fragment containing the putative minimal promoter of
CEACAM1 (600 bp upstream to CEACAM1 start codon), was
amplified and cloned into pGL4.14 LUC reporter vector (Promega,
Madison, WI) into XhoI/HindIII sites. Double mutations, mimicking
CEACAM1 SNPs (rs8103285 and rs8102519), were inserted using
QuikChangeMulti Site-DirectedMutagenesis Kit (Stratagene, La Jolla,
CA), according to manufacturer's protocol. Table W2 provides list of
primers used for putative minimal promoter cloning and mutagenesis.
Constructs and pRL Renilla Luciferase Reporter Vector (Promega,
Madison, WI, USA) were cotransfected into the cells using TurboFect
Transfection Reagent (Fermentas, Burlington, Canada). After
48 hours, cells were lysed, and luciferase activity was measured with
Dual Luciferase Reporter Assay System (Promega) and normalized to
Renilla. Assays were carried out in triplicate.Figure 1. CEACAM1 expression during melanoma development an
progression tissue microarray was studied with immunohistochemis
number of tested tissues from each stage is indicated in the bottom
indicated tissue cores from the tissue microarray is shown. (C) Low
were tested for the ratio between the long and short cytoplasmic tail C
(D) Ratio between long and short forms was determined for CEACAM
lines. Ratios were determined with variant-specific real-time PCR.Statistics
All data were analyzed using IBM (Chicago, IL, USA) SPSS
statistic software (version 19). P ≤ .05 was considered significant. All
graphs were generated using Microsoft Excel 2010 (Microsoft Inc,
Redmond, WA, USA) or GraphPad software (GraphPad Inc, La Jolla,
CA, USA) (version 6).
All assays were independently repeated at least three times. Two-
tailed paired t test was used to assess significance of all proliferation
assays in vitro. Mann-Whitney U test was used to assess significance of
assays in vivo. χ2 testing was performed to evaluate Hardy-Weinberg
equilibrium or deviation in the control and melanoma cases group.
Conventional methods for case-control studies were used to calculate
odds ratios [25], relative risks, and 95% confidence intervals (CIs) [6].
To test the significance of other data, two-tailed t test was used.
Results
CEACAM1 Expression Pattern in Melanoma
In light of the previously reported strong prognostic importance of
CEACAM1 expression in melanoma [18], it is imperative to define its
expression profile. We studied CEACAM1 expression in progression
tissue microarray that includes specimens of benign nevi, primary
melanoma, lymph node metastases, and remote metastases. Whereas
less than 10% of the nevi faintly express cell surface CEACAM1, a
gradual, prominent up-regulation was observed along disease
progression, reaching 50% of the cases of remote metastases (Figure 1,
A and B). This indicates that neoexpression of CEACAM1 is initiated
in some of the primary tumors but commonly develops along the
course of tumor progression. CEACAM1 expression was observed in
two NIH-established melanoma cell lines and in four of sevend progression. (A) CEACAM1 expression analysis of melanoma
try. Figure shows the percentage of CEACAM1-positive cases. The
. (B) Representative immunohistochemistry staining with MRG1 of
-passage primary cultures of metastatic melanoma cells (n = 40)
EACAM1 splice variants. Horizontal dash line represents ratio of 1.
1 isoforms with three or four extracellular domains in melanoma cell
Figure 2. CEACAM1-Long facilitatesmelanoma cell growth. (A) Stable CEACAM1 knockdownwith two different shRNAclones or scrambled
sequence as control. Figure shows surface CEACAM1 expression in flow cytometry using MRG1 mAb. (B) CEACAM1-knockdown clones
tested for cell proliferation, as tested with standardized XTT colorimetric assay. Figure shows a representative experiment out of three
independently performed experiments. Significance was tested with paired t test (scramble data vs each clone). (C) CEACAM1-Long
(CCM1-L) or empty (Mock) vectors were overexpressed in CEACAM1-negative 003mel. Figure shows surface CEACAM1 expression as
tested by flow cytometry. (D) CEACAM1 overexpression or control cells were tested for proliferation with standardized XTT colorimetric
assay. Figure shows a representative experiment out of three independently performed experiments. Significance was tested with
paired t test. (E) CEACAM1 overexpression or control cells were injected subcutaneously into SCID-NOD mice. Figure shows average
tumor volume measurements over time. Each group included eight animals. Figure shows a representative experiment out of three
independently performed experiments. Significance was tested with Mann-Whitney U test. (F) Representative macroscopic images of
extracted tumors are indicated in the figure. (G) Average CEACAM1 expression in the extracted xenografts, as testedwith real-time PCR.
Significance was tested with nonpaired t test. Y-axis denotes ΔCt after normalizing to the housekeeping gene GAPDH. Error bars
throughout the figure reflect SE. *, **, and *** denote significance values of P b .05, P b .01, and P b .001, respectively.
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between Long and Short CEACAM1 variants was tested with isoform-
specific real-time PCR in 40 CEACAM1-positive low-passage primary
cultures of metastatic melanoma. Notably, a clear dominance of the
Long form was observed (Figure 1C). Dominance of the long
cytoplasmic tail form was similarly observed in alternatively spliced
isoforms containing three or four extracellular domains (Figure 1D).CEACAM1 Facilitates the Proliferation of Melanoma Cells
The direct effect of CEACAM1 on the proliferation of melanoma
cells was tested by selective, stable knockdown, using small hairpin
RNA (shRNA) in 526mel cells. Transfection with a nontarget
scrambled sequence served as negative control. The expression of
CEACAM1 was decreased by 50% using two different shRNA
sequences as confirmed by flow cytometry (Figure 2A). A significant
456 CEACAM1 Facilitates Melanoma Cell Proliferation Ortenberg et al. Neoplasia Vol. 16, No. 5, 2014inhibition in the net proliferation of both knockdown clones was
observed, compared to the control cells (P b .001; Figure 2B).
Moreover, similar results were observed in three additional established
cell lines, WM-266-4, SK mel 5, and MeWo (Figure W2, A–C). The
proliferation of another established cell line, SK mel 28, was unaffected
by CEACAM1 knockdown (Figure W2D). Complementarily, CEA-
CAM1-negative melanoma culture 003mel was stably transfected with
the CEACAM1-Long cDNA (003/CCM1-L), the dominant CEA-
CAM1 isoform (Figure 1C). Transfection with an empty PQCXIP
vector served as negative control (003/Mock). The expression of
CEACAM1 was confirmed by flow cytometry (Figure 2C). In this cell
system, a significant enhancement in net proliferation was observed in
the CEACAM1-transfectanted cells (P b .01; Figure 2D).
The melanoma growth–promoting effect was further tested in vivo.
Cells (003/Mock or 003/CCM1-L) were injected subcutaneously into
SCID-NOD mice, which were monitored for tumor growth rates.
Importantly, the average tumor growth rate of 003/CCM1-L tumors
was significantly higher than that of tumors arising from injection ofFigure 3. Defining CEACAM1 protein components required to facil
indicated in the left. Long, CEACAM1-Long; Short, CEACAM1-Short;
CT-S, short cytoplasmic tail; GPI, glycosyl phosphoinositol link; GFP,
CEACAM1-negative 003mel cells. Similar expression was validated
portion of CEACAM1. Spontaneous fluorescence was observed for G
GFP-CT-L cells. (D) Average proliferation fold after 2 days for ea
standardized colorimetric XTT assay. Figure shows the average of
indicated transfectants, as measured by DNA content with flow cyto
cells (S-G2-M). Figure shows the average of three independent experi
incubated with various concentrations of the CEACAM1-blocking
standardized colorimetric XTT assay. The figure shows the average o003/Mock (Figure 2E). Extraction of all tumors after 5 weeks showed
the macroscopic differences between 003/Mock and 003/CCM1-L
tumors (Figure 2F). The expression of CEACAM1 was maintained
in vivo (Figure 2G). Collectively, the combined in vitro and in vivo data
strongly suggest that CEACAM1 directly enhances the proliferative
potential of melanoma cells and, accordingly, their tumorigenicity.
Proliferation Is Facilitated Only By the Long Isoform of
CEACAM1
In other cell systems, such as lymphocytes, it was suggested that
CEACAM1 with short-tail is associated with activation, whereas the
long-tail isoform is associated with inhibition [10,12,13,26]. In
addition, it was reported that regulation of insulin clearance in the
liver or of proliferation rate in colon cells are independent from the
extracellular portion of CEACAM1 [27,28]. Therefore, the following
series of constructs were made and stably transfected into the
CEACAM1-negative 003mel cells: CEACAM1-Long tail (Long),
CEACAM1-Short tail, CEACAM1 without a cytoplasmic tailitate proliferation. (A) Description of the constructs generated as
EC, extracellular; TM, transmembrane; CT-L, long cytoplasmic tail;
green fluorescent protein. (B) All constructs were transfected into
by flow cytometry for all constructs containing the extracellular
FP-CT-L. (C) Western blot for CEACAM1 or GFP on control, Long, or
ch of the indicated transfectants. Proliferation was tested with
six independent experiments. (E) Cell cycle measurements of the
metry. Cells were grouped into resting cells (G0-G1) or proliferating
ments. (F) CEACAM1-positive cells, as indicated in the figure, were
mAb MRG1 and tested for proliferation fold after 2 days with
f three independent experiments.
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(EC-GPI), and the transmembrane with long tail portions fused
downstream to GFP preceded by the leader peptide of CEACAM1
(GFP-CT-L) (Figure 3A). Flow cytometry using a CEACAM1-specific
mAb to CEACAM1 confirmed similar expression levels of all constructs,
except for the somewhat lower expression level of EC-GPI (Figure 3B).
It is impossible to quantitatively compare the endogenous fluorescent
signals of the GFP construct with the signals of the other CEACAM1
constructs, which emanate from FITC-conjugated secondary
antibodies. Western blot analysis with anti-GFP confirmed that the
GFP-CT-L protein was expressed similarly to CEACAM1-L
(Figure 3C). Only the 003/CCM1-L cells displayed a consistently
enhanced net proliferation compared to 003/Mock cells (Figure 3D).
This was further supported in cell cycle analyses, which demonstrated a
clear shift of almost 20% of the 003/CCM1-L cell population from
resting G0-G1 phase to proliferating S-G2-M phase (Figure 3E).
Importantly, blocking of intercellular homophilic CEACAM1 interac-
tions with a blocking mAb [17] did not inhibit the net proliferation of
526mel or 003/CCM1-L cells over a wide range of concentrations
(Figure 3F). In conclusion, the combined results suggest that both
extracellular portion and long cytosolic tail of CEACAM1 are required
to enhance melanoma cell proliferation but that the mechanism may
not involve homophilic intercellular CEACAM1 interactions.Figure 4. CEACAM1-Long enhances proliferation in a Sox-2-dependent
as detected by Affymetrix oligonucleotide expression microarray. Gene
denotes the number of altered genes. (B) Sox-2 expression in the indic
(D) Sox-2 was knocked downwith small interference RNA (siRNA) in 00
time PCR (left) or protein level withWestern blot (right). Scrambled RNA
003/Long cells transfected with scrambled RNAi or Sox-2–specific RN
representative experiment of three experiments performed independeCEACAM1 Enhances the Proliferation of Melanoma Cells in a
Sox-2–Dependent Manner
A comparative whole-genome oligonucleotide microarray indicated that
more than 650 genes were differentially expressed in a significant manner
(N2- or b0.5-fold) among the 003/Mock and 003/CCM1-L cells. In
agreement with the in vitro and in vivo observations (Figure 2), the most
prominent functional gene clusters included cell growth and proliferation
(N120 genes) and also other potentially related clusters such as cell
development (about 120 genes), cell movement (about 100 genes), cell-cell
interaction (about 90 genes), and other functions (Figure 4A). The array
was successfully validated by testing several genes that were upregulated or
downregulated in the 003/CCM1-L cells with real-time PCR (FigureW3).
It was recently reported that the stem cell factor Sox-2 is upregulated in
melanoma aswell as in some epithelial cancers [29–31]. Importantly, Sox-
2 was significantly upregulated following overexpression of CEACAM1-
Long both in the RNA and protein levels (Figure 4, B andC). Moreover,
no similar up-regulation of Sox-2 was observed in cells transfected with
CEACAM1-Short or with a construct lacking the entire extracellular
portion (Figure 4B). This result is in agreement with the effect of
CEACAM1 on proliferation (Figure 3D). Whereas it was previously
shown that Sox-2 enhances the invasive capacity of melanoma cells [32],
successful knockdown of Sox-2 in 003/CCM1-L, evident both in RNA
and protein levels (Figure 4, D and E), remarkably reduced the netmanner. (A) Gene clusters altered in 003/Long versus 003/Mock cells
s were clustered according to functional groups, as indicated. Y-axis
ated transfectants using real-time PCR or (C) Western blot is shown.
3/Long cells, and the effect wasmonitored at the RNA level with real-
i sequence was used as control. (F) Figure shows the proliferation of
Ai using standardized colorimetric XTT assay. The figure shows a
ntly. Significance was tested with paired t test.
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other melanoma lines (data not shown).
Novel SNP Enhances the CEACAM1 Promoter Activity
We next analyzed the promoter of CEACAM1 for the presence of
SNPs. Overall, 267 individuals were genotyped (134 patients with
melanoma and 133 ethnically matched control cases). In the first
genotyping assay, 75 patients with melanoma were genotyped for
14 CEACAM1 SNPs that matched the selection criteria: 3 SNPs in
5'UTR—rs41416852, rs8103285, and rs8102519; 3 SNPs in the
coding region, which potentially causemissensemutations—rs8111468,
rs8110904, and rs8111171; and 8 SNPs in 3'UTR—rs111284121,
rs1047943a, rs14774, rs76779598, rs1047942, rs138145530,
rs1047941, and rs150410858. In 12 of the 14 tested SNPs, all patients
were homozygote for the common allele. The only two SNPs that
showed variation in allele distribution were rs8103285 and rs8102519,
located in the 5'UTR of CEACAM1. These two SNPs are near each
other (62 bp) and thus are in linkage disequilibrium.
A genomic fragment upstream to the coding region of CEACAM1,
which is known to carry promoter activity [33,34], was cloned upstream
to luciferase reporting gene.The promoter activitywas shownusing IFNγ
(Figure W4). To study the potential functional effect of these SNPs on
the promoter activity of CEACAM1, a series of point mutations were
introduced into the wild-type construct mimicking each of the SNPs
separately and together. All of the constructs were cotransfected with
Renilla-expressing vector into different melanoma cells, and normalized
luciferase activity was measured. Remarkably, the wild-type promoter
exhibited a significantly lower activity compared to the single and double
SNP constructs in all melanoma cell lines (Figure 5B). Transfection of an
empty vector with no promoter upstream to the luciferase hardly
produced measurable signals (Figure 5B). This observation strongly
indicates that these SNPs enhance the promoter activity of CEACAM1.
Both SNPs contribute to this enhanced activity, but the genetically
relevant construct is the double SNP, as these SNPs occur together being
in linkage disequilibrium.
Germ Line Genotype Carrying the Double SNP in the
CEACAM1 Promoter Enhances the Risk to Develop Melanoma
To evaluate the medical relevance of the promoter enhancing SNPs, we
tested their frequency in the germ line of 134 patients withmelanoma and
in 133 ethnicallymatched healthy controls. In the control group, the SNPsFigure 5. Functional SNPs in the promoter of CEACAM1. (A) Part s
studied SNPs are bolded and enlarged. (B) Functional fragments of th
WT), each SNP (SNP85 or SNP19), or both (SNP85 + SNP19) were
promoter constructs were transfected and tested for luciferase activ
wild-type promoter was set as the point of reference. Figure showsdisplayed no deviation from Hardy-Weinberg equilibrium; however, the
patients with melanoma showed a statistically significant deviation,
suggesting an association between these SNPs in CEACAM1 5'UTR and
melanoma phenotype. Results show an association between melanoma
and homozygosity to the rare alleles of SNPs rs8103285 and rs8102519,
with an allelic Odds Ratio (OR) of 2.05 (95% CI = 0.86-0.49; P = .1).
Remarkably, homozygosity to these alleles conferred increased risk to
melanoma with relative risk of 1.35 (95% CI = 1.01-1.81; P = .05).
Discussion
Expression analysis in various types of cancer shows that CEACAM1 is
overexpressed in some malignancies, such as melanoma, lung cancer, and
thyroid carcinoma, whereas it is downregulated in colon, prostate,
endometrial, and breast cancers [35]. CEACAM1 exerts tumor-
suppressive effects in colon [21], prostate [22], and breast cancer cells
[36], which could explain its loss in these types of cancers. However, in
melanoma and lung cancer, the presence of CEACAM1 is known to
strongly predict the development of aggressive disease with poor outcome
[18,37,38]. The only mechanistic explanation potentially accounting for
this clinical observation was that CEACAM1 directly inhibits activated
NK and T lymphocytes [8,15,18,37,38]. There was no information
regarding the direct effects of CEACAM1 on melanoma cells.
Here, we found that CEACAM1 is gradually upregulated along
melanoma development and progression (Figure 1), as opposed to the
acquired mutation in BRAF, which is observed already at the stage of
nevus [39]. Analysis of metastatic melanoma cultures shows
predominance of the CEACAM1-Long tail (Figure 1). Knockdown
or overexpression of CEACAM1-Long directly led to inhibition or
facilitation of proliferation in vitro, respectively. CEACAM1-Long
overexpression further facilitated in vivo xenograft tumorigenicity of
melanoma (Figure 2). Thus, CEACAM1 has a dual role in
melanoma, as it provides direct protection from late effector
lymphocytes [8,15] and exerts oncogenic effects. This is in line
with the gradual up-regulation along disease progression.
CEACAM1 inhibits proliferation of colon cancer cells even in the
absence of its entire extracellular domain [27]. Similarly, CEACAM1
regulates insulin clearance by cytoplasmic tail interactions with insulin
receptor [40]. Conversely, homophilic intercellular interactions are the
cornerstone of lymphocyte inhibition by CEACAM1 [8,13,15], which
can be targeted with mAbs [17]. By employing a cell system of
CEACAM1 truncated mutants, we positively show that both theequence of the CEACAM1 promoter. ATG and the location of the
e CEACAM1 promoter carrying the consensus nucleotides (pCCM1
cloned upstream to a luciferase reporter. Empty vector (Mock) or
ity in various melanoma cell lines, as indicated. The activity of the
an average of three independent experiments performed.
Table 1. SNP Distribution in Patients with Melanoma and Healthy Donors
Patients with Melanoma Healthy Donors
N = 134 N = 133
Genotype Counts
Consensus nucleotides 94 (70.1%) 83 (62.4%)
Double SNPs, heterozygote 32 (23.9%) 46 (34.6%)
Double SNPs, homozygote 8 (6%) 4 (3%)
χ2 4.73 0.63
Hardy-Weinberg equilibrium No Yes
The overall frequencies of rs8103285 and rs8102519 in a cohort of 134 patients with melanoma
and 133 healthy donors are displayed. Hardy-Weinberg equilibrium (χ2) of population of both
groups was calculated groups using the conventional method.
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melanoma cell proliferation (Figure 3). Interestingly, antibodies that
block the N-domain of CEACAM1 failed to affect proliferation
(Figure 3). CEACAM1 is known to bind heterotypically to CEACAM5
[41] or to various bacterial proteins [7], none of which are found in
melanoma cells. However, it was previously shown that CEACAM1
exerts cis-interactions with integrins, such as integrin β3, as previously
reported [42]. Preclinical studies with anti–integrin αvβ3 mAb reported
on inhibition of tumor proliferation [43]. It is still unclear whether this
integrin is an effector of CEACAM1 in enhancing melanoma cell
proliferation. The protein partner of CEACAM1 enabling the
facilitation of proliferation in melanoma cells remains to be identified.
The up-regulation of CEACAM1-Long inmelanoma cells triggers the
expression of many functional gene groups that are associated with the
observed phenotype (Figures 3 and 4). Sox-2, which was upregulated by
CEACAM1-Long at the RNA and protein levels, was proven
instrumental in enhancing the proliferation ofmelanoma cells (Figure 4).
Sox-2 is one of the Yamanaka factors associated with induction of
inducible pluripotent stem cells [44]. The role of Sox-2 was very
limitedly investigated in melanoma cells. Previously reported expression
analyses demonstrated a gradual up-regulation from 14% in nevi and up
to 80% in metastatic melanoma [30], which resembles the expression
profile of CEACAM1 (Figure 1). In addition, it was shown that Sox-2
enhances the invasive capacity of melanoma cell [32]. Interestingly,
Sox-2 enhances metastasis of breast and prostate cancer cells by
promoting of WNT/β-catenin signaling. Dual luciferase assay and
chromatin immunoprecipitation revealed activation and binding of Sox-
2 to the promoter region of β-catenin [45]. Recently, it was identified
that Armadillo repeats of β-catenin binds to the H469 and K470 in the
cytoplasmic domain of CEACAM1 long cytoplasmic tail [46], which
enables redistribution of β-catenin to the cytoskeleton and inhibition of
its degradation [47]. We speculate that, in melanoma, CEACAM1
overexpression and the subsequently induced Sox-2 culminate in
enhanced expression of β-catenin by Sox-2 and its protection from
degradation by the long cytoplasmic tail of CEACAM1. Indeed, the
Wnt/β-catenin pathway is overactive in melanoma, facilitating
oncogenic and chemoresistant properties [48]. The postulated role of
CEACAM1 and Sox-2 in activating Wnt/β-catenin pathway in
melanoma remains to be tested.
To delineate factors contributing to the increased CEACAM1
expression in melanoma, we studied its promoter. Bioinformatics
analysis pointed on a hypothetical M-Box for MITF in the promoter.
However, we failed to positively show any regulation of CEACAM1
promoter by MITF-M (data not shown). SNP analysis pointed on two
extremely close positions upstream to the ATG; each significantly
enhances its activity in melanoma cells (Figure 5). Due to the close
proximity, they are inherited together. Sequencing of 134 germ-line
DNA samples derived from patients with melanoma and 133 samples
from matched healthy donors reveals that, whereas the healthy donor
population complies with the Hardy-Weinberg equilibrium, the
population of the patients with melanoma deviates from it significantly,
attesting for an association between these SNPs and melanoma.
Moreover, germ-line homozygosity increases the chances to develop
melanoma by 35% (Table 1). This observation is consistent with the
enhanced promoter activity conferred by these SNPs (Figure 5), which
could lower the threshold for CEACAM1 expression, and thereby
enhance proliferation and immune evasion effects. It is still unclear why
these SNPs increase the promoter activity. One possibility could be
alteration of putative binding sites for transcription factors or repressors.By employing predictive tools, such as PROMO [49], new putative
binding sites for various transcription factors, such as signal transducer
and activator 4 (STAT4), ETS1-v-ets avian erythroblastosis virus E26
oncogene homolog 1, and ELK-1, are generated by these SNPs. Thus,
the SNP genotype in the promoter of CEACAM1 is not just a statistical
marker for enhanced risk but also rather reflects a mechanism. At the
moment, there are only a few genetic markers for enhanced risk to
develop melanoma: cyclin-dependent kinase inhibitor 2A (CDKN2A),
cyclin-dependent kinase 4 (CDK4), The melanocortin 1 receptor
(MC1R), and some other low-risk markers such as tyrosinase (TYR),
vitamin D receptor (VDR), and HLA-DQB0301 [50]. CEACAM1
genotyping might be used in the future to identify high-risk
populations, but first, these findings must be validated in larger cohorts.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.neo.2014.05.003.
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